Sendurai A Mani

List of Publications by Year in Descending Order

102 papers	19,891 citations	48 h-index	141 g-index
141 ext. papers	22,782 ext. citations	10 avg, IF	6.17 L-index

#	Paper	IF	Citations
102	A panel of emerging EMT genes identified in malignant mesothelioma.. *Scientific Reports*, **2022**, 12, 1007	4.9	2
101	In Vitro Quantification of Cancer Stem Cells Using a Mammosphere Formation Assay.. *Methods in Molecular Biology*, **2022**, 2429, 509-513	1.4	
100	Enrichment of Cancer Stem Cells in a Tumorsphere Assay.. *Methods in Molecular Biology*, **2022**, 2429, 501-507	1.4	
99	Limiting Dilution Tumor Initiation Assay: An In Vivo Approach for the Study of Cancer Stem Cells.. *Methods in Molecular Biology*, **2022**, 2429, 547-554	1.4	0
98	CD8 T cells inhibit metastasis and CXCL4 regulates its function. *British Journal of Cancer*, **2021**, 125, 176-189	8.7	3
97	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. *Npj Breast Cancer*, **2021**, 7, 66	7.8	8
96	Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	31
95	EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. *British Journal of Cancer*, **2021**, 124, 259-269	8.7	23
94	Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition. *Nature Communications*, **2021**, 12, 4262	17.4	3
93	Single-Cell Cloning of Breast Cancer Cells Secreting Specific Subsets of Extracellular Vesicles. *Cancers*, **2021**, 13,	6.6	2
92	A proteogenomic portrait of lung squamous cell carcinoma. *Cell*, **2021**, 184, 4348-4371.e40	56.2	15
91	Vimentin and cytokeratin: good alone, bad together.. *Seminars in Cancer Biology*, **2021**,	12.7	3
90	UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression. *Oncogene*, **2020**, 39, 3089-3101	9.2	14
89	Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature Reviews Molecular Cell Biology*, **2020**, 21, 341-352	48.7	469
88	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. *Cancers*, **2019**, 11,	6.6	55
87	GSK3 regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. *Breast Cancer Research*, **2019**, 21, 37	8.3	48
86	A possible role for epigenetic feedback regulation in the dynamics of the epithelial-mesenchymal transition (EMT). *Physical Biology*, **2019**, 16, 066004	3	47

85	The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing Expression. *Cancers*, **2019**, 11,	6.6	19
84	Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. *Frontiers in Oncology*, **2018**, 8, 69	5.3	7
83	EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1870, 229-238	11.2	28
82	Hybrid epithelial/mesenchymal phenotype(s): The Fittest for metastasis?. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1870, 151-157	11.2	76
81	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
80	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. *Oncologist*, **2017**, 22, 1086-1093	5.7	53
79	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. *Genome Biology*, **2017**, 18, 98	18.3	75
78	Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. *Nature*, **2017**, 544, 250-254	50.4	365
77	Epithelial-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs): The Traveling Metastasis. *Cancer Drug Discovery and Development*, **2017**, 67-80	0.3	2
76	A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E9903-E9912	11.5	37
75	Metal-Free Dual Modal Contrast Agents Based on Fluorographene Quantum Dots. *Particle and Particle Systems Characterization*, **2017**, 34, 1600221	3.1	20
74	Distinguishing mechanisms underlying EMT tristability **2017**, 1, 2		47
73	Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival.. *Journal of Clinical Oncology*, **2017**, 35, 1090-1090	2.2	2
72	The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. *Oncotarget*, **2017**, 8, 65548-65565	3.3	36
71	3D Porous Graphene by Low-Temperature Plasma Welding for Bone Implants. *Advanced Materials*, **2016**, 28, 8959-8967	24	43
70	Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. *Journal of the Royal Society Interface*, **2016**, 13,	4.1	84
69	FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition. *Scientific Reports*, **2016**, 6, 23070	4.9	15
68	High hardness in the biocompatible intermetallic compound Ti3Au. *Science Advances*, **2016**, 2, e1600319	14.3	34

67	Mathematical modelling of phenotypic plasticity and conversion to a stem-cell state under hypoxia. *Scientific Reports*, **2016**, 6, 18074	4.9	27
66	Three-Dimensional Porous Sponges from Collagen Biowastes. *ACS Applied Materials & Interfaces*, **2016**, 8, 14836-44	9.5	23
65	Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. *Oncogene*, **2016**, 35, 5977-5988	9.2	33
64	Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. *Oncogene*, **2016**, 35, 5963-5976	9.2	50
63	Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of Breast Cancer Cells by Reducing Membrane Fluidity. *Cancer Research*, **2016**, 76, 2037-49	10.1	74
62	Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?. *Cancer Letters*, **2016**, 380, 359-68	9.9	40
61	Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. *Journal of Clinical Investigation*, **2016**, 126, 2626-41	15.9	38
60	Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. *Oncotarget*, **2016**, 7, 40252-40265	3.3	28
59	Stability of the hybrid epithelial/mesenchymal phenotype. *Oncotarget*, **2016**, 7, 27067-84	3.3	259
58	The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states. *BMC Biology*, **2016**, 14, 47	7.3	26
57	GD2 and GD3 synthase: novel drug targets for cancer therapy. *Molecular and Cellular Oncology*, **2015**, 2, e975068	1.2	4
56	A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome. *Scientific Reports*, **2015**, 5, 11766	4.9	25
55	GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. *Oncogene*, **2015**, 34, 2958-67	9.2	76
54	Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. *Blood*, **2015**, 125, 2968-73	2.2	22
53	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. *PLoS ONE*, **2015**, 10, e0132710	3.7	69
52	Coupling the modules of EMT and stemness: A tunable ⊗temness window⊗model. *Oncotarget*, **2015**, 6, 25161-74	3.3	116
51	EMT-induced metabolite signature identifies poor clinical outcome. *Oncotarget*, **2015**, 6, 42651-60	3.3	39
50	Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. *Journal of the Royal Society Interface*, **2014**, 11, 20140962	4.1	126

49	Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes. *PLoS ONE*, **2014**, 9, e100249	3.7	40
48	Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. *Breast Cancer Research and Treatment*, **2014**, 143, 189-201	4.4	6
47	Abstract 2080: Plasma membrane fluidity drives metastasis in breast cancer **2014**,		2
46	Fluorinated graphene oxide; a new multimodal material for biological applications. *Advanced Materials*, **2013**, 25, 5632-7	24	140
45	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Research*, **2013**, 23, 1446-61	9.7	442
44	Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. *Cancer Letters*, **2013**, 341, 16-23	9.9	23
43	FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. *Cancer Research*, **2013**, 73, 1981-92	10.1	187
42	Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition: Yu M, Bardia A, Wittner BS, et al (Harvard Med School, Charlestown, MA) Science 339:580-584, 2013. *Breast Diseases*, **2013**, 24, 225-226		0
41	Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. *Cancer Cell*, **2013**, 23, 171-85	24.3	309
40	Synthesis of Fluorinated Graphene Oxide and its Amphiphobic Properties. *Particle and Particle Systems Characterization*, **2013**, 30, 266-272	3.1	93
39	BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. *Science Signaling*, **2013**, 6, ra2	8.8	34
38	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. *Scientific Reports*, **2013**, 3, 2687	4.9	94
37	Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. *Genome Biology*, **2013**, 14, R144	18.3	63
36	Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. *PLoS ONE*, **2013**, 8, e64169	3.7	63
35	Alternative origins of stroma in normal organs and disease. *Stem Cell Research*, **2012**, 8, 312-23	1.6	51
34	Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. *International Journal of Cancer*, **2012**, 130, 808-16	7.5	125
33	Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. *Breast Cancer Research*, **2012**, 14, R51	8.3	63
32	Slug and Sox9 cooperatively determine the mammary stem cell state. *Cell*, **2012**, 148, 1015-28	56.2	685

31	Hybrid 2D nanomaterials as dual-mode contrast agents in cellular imaging. *Advanced Materials*, **2012**, 24, 2992-8	24	58
30	Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. *Cancer Medicine*, **2012**, 1, 5-16	4.8	171
29	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 2526-34	6.1	165
28	Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis. *Oncogene*, **2012**, 31, 2237-46	9.2	55
27	Fluorescent Superparamagnetic Iron Oxide Core–Shell Nanoprobes for Multimodal Cellular Imaging. *Materials Express*, **2012**, 2, 265-274	1.3	6
26	Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. *Journal of Clinical Investigation*, **2012**, 122, 2066-78	15.9	184
25	HDAC3 at the fulcrum of an epithelial-mesenchymal balance. *Molecular Cell*, **2011**, 43, 697-8	17.6	3
24	Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. *Breast Cancer Research*, **2011**, 13, 202	8.3	249
23	Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. *Cancer*, **2011**, 117, 2408-18	6.4	19
22	Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15449-54	11.5	759
21	Molecular mechanisms of metastasis in breast cancer--clinical applications. *Nature Reviews Clinical Oncology*, **2010**, 7, 693-701	19.4	179
20	Correction for Taube et al., Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19132-19132	11.5	5
19	Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **2010**, 15, 235-52	2.4	230
18	Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. *Stem Cells*, **2010**, 28, 1435-45	5.8	190
17	Breast cancer metastasis: challenges and opportunities. *Cancer Research*, **2009**, 69, 4951-3	10.1	152
16	The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. *Journal of Mammary Gland Biology and Neoplasia*, **2009**, 14, 29-43	2.4	292
15	The importance of the epithelial-mesenchymal transition in breast cancer. *Current Breast Cancer Reports*, **2009**, 1, 229-237	0.8	6
14	The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*, **2008**, 133, 704-715	56.2	6611

13	Cell type-specific DNA methylation patterns in the human breast. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 14076-81	11.5	191
12	Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Research*, **2008**, 68, 3645-54	10.1	1100
11	Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 10069-74	11.5	446
10	Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. *Cancer Research*, **2007**, 67, 8131-8	10.1	158
9	Exploring a new twist on tumor metastasis. *Cancer Research*, **2006**, 66, 4549-52	10.1	254
8	Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell*, **2004**, 117, 927-39	56.2	2996
7	Phenobarbitone-mediated translocation of the cytosolic proteins interacting with the 5′-proximal region of rat liver CYP2B1/B2 gene into the nucleus. *Biochemical and Biophysical Research Communications*, **2002**, 292, 312-7	3.4	3
6	Receptor-mediated gene delivery approach demonstrates the role of 5′-proximal DNA region in conferring phenobarbitone responsiveness to CYP2B2 gene in rat liver in vivo. *Biochemical and Biophysical Research Communications*, **2000**, 268, 734-9	3.4	8
5	Evaluation of splenomegaly in portal hypertension. *Journal of Clinical Gastroenterology*, **1996**, 22, 28-30	3	14
4	Ultrasonic evaluation of portosystemic collateral circulation in portal hypertension. *Journal of the Association of Physicians of India, The*, **1996**, 44, 537-9	0.4	
3	A model for the transcriptional regulation of the CYP2B1/B2 gene in rat liver. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 9628-32	11.5	31
2	Distinguishing Mechanisms Underlying EMT Tristability		2
1	A possible role for epigenetic feedback regulation in the dynamics of the Epithelial-Mesenchymal Transition (EMT)		1